Osage University Partners — 2024 Investments
1 investments dated 2024 · listed companies and verified rows first · show all
Nocion Therapeuticsnociontx.comin𝕏Mar 2024
Nocion Therapeutics develops small molecule charged sodium channel blockers (nocions) designed to silence overactive sensory nerves.
BiotechHealthtechMedical DevicesWatertown, US
MATTHEW FRANKEL(Executive Officer)inPETER COUROSSI(Executive Officer)RICHARD BATYCKY(Executive Officer, Director)JAMES ELLIS(Executive Officer)MICHAEL LIPP(Executive Officer)inCHRISTOPHER SILBER(Executive Officer)in
Co-investorsCanaan PartnersF-Prime CapitalMission BiocapitalMonograph Capital PartnersOUP (Osage University Partners)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.